More than 90% of the targets of therapeutic antibody drugs or immunotherapies are membrane proteins (MPs);

There are about 7,000 known MPs in the human body. The vast majority have not yet been thoroughly studied. Even so, more than 60% of FDA-approved drugs target MPs；

From 2013 to 2022, the market size of drugs targeting MPs grew to account for over 50% of that of blockbuster drugs；

It is expected that, in the future, drugs targeting MPs will usher in more breakthroughs in cancer treatments, autoimmunity diseases, pain management, cardiovascular and neurodegenerative disease treatments；